These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: First vaccine designed for Africa cleared for testing in humans.
    Journal: AIDS Wkly; 2000 Jul 24; ():2-4. PubMed ID: 12296005.
    Abstract:
    During the International AIDS Conference in Durban, South Africa, the International AIDS Vaccine Initiative (IAVI) announced that a DNA vaccine based on HIV subtype A has been approved for testing in humans. This vaccine, designed specifically for Africa, has been noted to have a very good chance of stimulating cellular immune responses to HIV. Extensive studies on sex workers in Nairobi found that, despite frequent exposure to HIV, a small minority of these women has resisted infection over many years. In addition, research has also suggested that white blood cells activated by the DNA vaccine can destroy virus-infected cells. Coinciding with the news was the release of the Scientific Blueprint 2000, a global strategic research and development agenda from IAVI. This report concluded that developing an effective AIDS vaccine in the shortest possible time will require a widening of the vaccine pipeline, compressed timeliness for clinical trials, greater focus on the needs of developing countries and more funding. To this effect, the report calls for the implementation of several initiatives for the realization of the scientific program of IAVI.
    [Abstract] [Full Text] [Related] [New Search]